Quintiles

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Quintiles Transnational
Public
Traded as NYSEQ
Industry Contract Research Organization
Pharmaceutical Service Consulting
Founded 1982
Key people
Dennis Gillings, Executive Chairman
Tom Pike CEO
; Paula Brown Stafford, President Clinical
Products Support services for pharmaceutical, biotech and medical companies and individuals
Revenue IncreaseUS$ Approximately $4.2 billion in Service Revenue (2014)[citation needed]
Number of employees
~ 32,000 (2015)
Website http://www.quintiles.com/

Quintiles Transnational (NYSE: Q), is a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 32,000 employees conducting business in approximately 100 countries.

Quintiles is the world’s largest contract research organization as ranked by reported service revenues,[citation needed] and is focused primarily on Phase II-IV clinical trials and associated laboratory and analytical services. Quintiles' Integrated Healthcare Services supports diverse functions, including contract pharmaceutical sales in many geographic markets, as well as a growing number of healthcare business services, such as outcome-based and payer/provider services.

History[edit]

Quintiles was founded in 1982 by Dennis Gillings, Ph.D., CBE, then a professor of biostatistics at the University of North Carolina, Chapel Hill.[1]

Key Dates:

  • 1974: Dennis Gillings signs first contract to provide statistical and data management consulting for pharmaceutical clients.
  • 1982: Quintiles, Inc., is incorporated in North Carolina.
  • 1990: Quintiles Pacific Inc. and Quintiles Ireland Ltd. established
  • 1991: Quintiles GMBH established in Germany; Quintiles Laboratories Ltd. established in Atlanta, Georgia
  • 1996: Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world's largest CRO[2]
  • 1997: Quintiles goes public, completing successful secondary stock offering.
  • 1998: Quintiles is the first company in industry to break the $1 billion mark, when it reported net revenues of $1.19 billion.
  • 1999: Company joins the S&P 500 Index.
  • 2003: Board of Directors agrees to merge with Pharma Services Holdings Inc; Quintiles becomes a private company.
  • 2009: Quintiles opens new corporate headquarters in Durham, North Carolina
  • 2010: Quintiles opens new European headquarters in the UK and establishes operations in East Africa.
  • 2011: Quintiles buys Advion Biosciences, a bioanalytical lab based out of Ithaca, New York
  • 2013: Quintiles files for an IPO on 15 February in order to go public again [3]
  • 2013: Quintiles begins trading on the New York Stock Exchange (NYSE) under ticker symbol Q [4]

References[edit]

  1. ^ "Money, Math and Medicine". Forbes Magazine. November 22, 2010. Retrieved April 14, 2011. 
  2. ^ "High-Flying Quintiles to Buy Innovex in $747.5 Million Deal". New York Times. October 8, 1996. Retrieved April 14, 2011. 
  3. ^ http://www.sec.gov/Archives/edgar/data/1478242/000119312513062656/d483912ds1.htm
  4. ^ Wall Street Journal, May 9, 2013

External links[edit]